Unlimited shares is never good let alone in the OT
Post# of 22940
Posted On: 12/17/2016 8:39:23 AM
Unlimited shares is never good let alone in the OTC. Despite all assurances it can still be used for a printing press. Accoring to company/IR - company will have a minimum of $13.5MM from first SLA and from the last 8K - another $1MM. That is without any big EIA revenues or MRVB. Just with reported - that is $14.5 for next year. Compqny is 4.4BB of 4.5BB AS and at current rate will surpass that in 1-2 weeks (may e slower with holidays). After that - the rate will accelerate quickly as every tick becomes a lot more shares (converting at 1 gets twices as many as 2). Saving $9K and putting a major question mark in eyes of investors when company has committed to $14.5MM seems suspect at best. Worse when IR did not comment on AS being raised or buyback commencing for the last several weeks as this critical point was being approached.
I do appreciate Bill's comments via Twitter. Assuming at face value this had more to do with the Nevada irregularities vs total authorized, it is easier to accept. However, if that is the case, it would nice to see some strongly worded language/guidance from him on when buyback will commence (or the mysterious triggers IR alludes to), if it has started and how many, and reaffirm revenue guidance for 2017. Unfortunately - shareholders heard/read similar commitments at the end of 2015. Business is always dynamic but in the OTC, one has to be extra diligent in communicating and executing to rise above the majority of shells and scams littering the space. Right rnow, shareholders have seen $109K of revenues booked for 2016 and has yet to be paid. 4Q should be producing revenue but nowhere close to original guidance. Now shareholders are told the company has provided itself a blank check to save $9K a year. While I tend to be miserly both professionally and personally and appreciate the thrift - I am also very aware of expectations when dealing with customers and will spend according to their expectations (dinner, entertainment, etc).
If buyback doesntstart imminently - company could start adding 0.5BB a month to OS at current rate and dropping PPS. Since we dont know how many preferreds are there to be converted - hard to evaluate impact.
At face value - change isnt cataclysmic. In the OTC world - if it doesnt give you major pause - you are in the wrong space. Hoping Bill provides some solid reassuarance on numbers and timeline for those who not only stayed invested through the big runs but also were buying on the way down.
I do appreciate Bill's comments via Twitter. Assuming at face value this had more to do with the Nevada irregularities vs total authorized, it is easier to accept. However, if that is the case, it would nice to see some strongly worded language/guidance from him on when buyback will commence (or the mysterious triggers IR alludes to), if it has started and how many, and reaffirm revenue guidance for 2017. Unfortunately - shareholders heard/read similar commitments at the end of 2015. Business is always dynamic but in the OTC, one has to be extra diligent in communicating and executing to rise above the majority of shells and scams littering the space. Right rnow, shareholders have seen $109K of revenues booked for 2016 and has yet to be paid. 4Q should be producing revenue but nowhere close to original guidance. Now shareholders are told the company has provided itself a blank check to save $9K a year. While I tend to be miserly both professionally and personally and appreciate the thrift - I am also very aware of expectations when dealing with customers and will spend according to their expectations (dinner, entertainment, etc).
If buyback doesntstart imminently - company could start adding 0.5BB a month to OS at current rate and dropping PPS. Since we dont know how many preferreds are there to be converted - hard to evaluate impact.
At face value - change isnt cataclysmic. In the OTC world - if it doesnt give you major pause - you are in the wrong space. Hoping Bill provides some solid reassuarance on numbers and timeline for those who not only stayed invested through the big runs but also were buying on the way down.
(5)
(0)